#Italy #Milan #Diagens Biotechnology #iMedImage #Karyotype AI

Breakthrough in Genetic Analysis at ESHG 2025

The European Society of Human Genetics (ESHG) 2025 conference, which took place in Milan, Italy, from May 24 to 27, brought together experts from across the globe to discuss recent innovations in genetic research and technology. Among the many exhibitors, Hangzhou Diagens Biotechnology Co., Ltd. made headlines with its impressive display of the Rapid AI Karyotype Total Solution. This innovative approach was met with widespread acclaim from attendees, marking a significant moment in the evolution of genetic analysis.

Cutting-Edge Technology Unveiled

Diagens' AI Karyotype Total Solution is built upon the iMedImage® platform, which is recognized worldwide for its excellence in medical imaging. This comprehensive solution integrates several advanced technologies: an automatic cell harvester, a slide preparation and staining machine, a cell microscopy scanning system, and an intelligent chromosome karyotyping analysis system. The fusion of these technologies results in a highly automated laboratory setup, capable of efficiently transitioning from sample input to final report output without manual intervention.

The benefits are substantial. By introducing full automation, the solution enhances the speed and quality of sample processing while substantially cutting costs. This state-of-the-art system represents a paradigm shift in the laboratory environment, where redundancy is eliminated, and efficiency is maximized.

Insights from Leading Experts

During the conference, Professor Liang Desheng from Central South University presented a compelling poster titled "iMedImage®: An End-to-End Foundational Model for Medical Image Recognition and Its Application in Chromosome Analysis." His research underscored the significance of karyotyping, a vital technique for identifying chromosomal abnormalities that can lead to genetic conditions. Although AI has made great strides in identifying numerical abnormalities, the challenge of detecting structural abnormalities has persisted until now.

Professor Liang's findings demonstrated that the iMedImage® model excels in this realm, achieving an extraordinary diagnostic accuracy of 99.59%, with a sensitivity of 95.83% and a specificity rate of 100%. This remarkable performance extends across various medical imaging categories, including ultrasound, CT scans, and MRIs, showcasing its versatile applications in the medical field.

Global Recognition and Future Directions

The launch of Diagens’ Rapid AI Karyotype Total Solution not only marks a breakthrough in the use of AI for genetic analysis but also reinforces Diagens' reputation as a leader in AI-driven healthcare technology. With strong interest from clients in regions such as Europe, Africa, and South America, Diagens anticipates numerous partnerships aimed at advancing healthcare solutions through collaborative efforts.

As the global healthcare landscape evolves, Diagens remains committed to exploring the next frontiers in biotechnology and medical imaging. The company's dedication to innovation-driven development will undoubtedly contribute to significant advancements in genomic research and diagnostics. To learn more about Diagens and their pioneering solutions, visit www.diagens.com or contact them via email.

In conclusion, the ESHG 2025 conference has highlighted the growing role of technology in human genetics, with Diagens at the forefront of a revolution that will enhance our understanding of genetic disorders and improve patient outcomes through more accurate and efficient testing methods.